Chiron Corporation

Roche Molecular Systems, Inc.

Cetus Oncology Corporation

Janelle A Noble

Kirston E Koths

Robert F Halenbeck

George A Martin

Ernest S Kawasaki

Martha B Ladner

Mazie Yee Coyne

Henry A Erlich

Ann Begovich

Gary A Peltz

Teodorica L Bugawan

Rebecca Lynne Reynolds

Andrew Grupe

Gabriele Zangenberg

Ann Maria Valdes

Daniel B Mirel

Karen Myra Walker

The present invention provides methods and reagents for determining sequence variants present at the IL4 receptor, IL-4 and IL-13 loci, which facilitate identifying individuals at risk for type 1 diabetes.

Association of polymorphisms in IL4-related genes with autoimmune disease

Methods and reagents for determining sequence variants present at the TCF-1 locus, which facilitates identifying individuals at risk for Th1 diseases, such as type 1 diabetes or multiple sclerosis, or Th2 diseases, such as allergic asthma or atopy.

TCF-1 nucleotide sequence variation

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both 'long' and 'short' forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

Point mutants of N.gradient.2 CSF-1 and carboxy truncated fragments

N.gradient.2-CSF-1(long form) and carboxy truncated fragments thereof

DNA for new forms of CSF-1 are provided which relate to N-terminal and C-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short and long forms of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 149.

DNA encoding N- and C- terminally truncated colony stimulating factor-1

New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the long form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.

N- 3 deletion mutants of the long form of CSF-1

New forms of CSF-1 are provided which relate to N-terminal truncations. Specifically, N-.gradient.3 terminal truncations of the short form of CSF-1 have been found to be particularly advantageous. These forms may have a C-terminal truncation at a variety of different amino acids beyond position 150.

N-.gradient.3 deletion mutants of the short form of CSF-1

A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both 'long' and 'short' forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.

DNA encoding various forms of colony stimulating factor-1

Growing community of inventors

Berkeley, CA, United States of America

Janelle A Noble